The initial development of dapoxetine has been credited by some sources to Eli Lilly chemist David Wong, who was also one of the developers of fluoxetine (Prozac).
Like Prozac and other antidepressants such as Paxil and Zoloft, dapoxetine is a selective serotonin reuptake inhibitor (SSRI). In fact, following the drug's early development over a decade ago, Eli Lilly began phase I clinical trials for dapoxetine as an antidepressant medication.
- Dapoxetine didn't pan out as an antidepressant, and was shelved for a while. But the same thing that caused its failure as a psychopharmaceutical turned out to be the reason for its success as a treatment for premature ejaculation.
- The rights and patents for the drug have changed hands a few times, and several pharmaceutical companies have their fingers in the dapoxetine pie. The drug was originated by Eli Lilly, but in 1998, PPD GenuPro acquired the rights and from Eli Lilly to develop the drug as a premature ejaculation treatment.
- Dapoxetine will be marketed in the US by Ortho McNeil, by Janssen-Ortho Inc. in Canada, and is currently being marketed in Europe by Janssen-Cilag; these are all units of Johnson & Johnson.
- Despite its success in clinical trials, dapoxetine has still not been approved by the FDA. In December 2004, ALZA submitted a new drug application to the FDA for dapoxetine hydrochloride. Ten months later, the FDA responded by issuing a "not approvable" letter for the drug. Nevertheless, development of the drug continued and Johnson & Johnson initiated additional clinical trials to address the drug's possible risks and side effects.
Entradas
No hay comentarios:
Publicar un comentario